Lauren A Eberly1,2,3,4, Lin Yang2, Nwamaka D Eneanya4,5, Utibe Essien6,7, Howard Julien1,2,3, Ashwin S Nathan1,2,4, Sameed Ahmed M Khatana1,2,3,4,6, Elias J Dayoub1,2, Alexander C Fanaroff1,2,4, Jay Giri1,2,4, Peter W Groeneveld2,4,8,9, Srinath Adusumalli1,2,3,4. 1. Cardiovascular Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 2. Center for Cardiovascular Outcomes, Quality, and Evaluative Research, University of Pennsylvania, Philadelphia. 3. Penn Cardiovascular Center for Health Equity and Social Justice, University of Pennsylvania, Philadelphia. 4. Leonard Davis Institute of Health Economics at the University of Pennsylvania, Philadelphia. 5. Renal-Electrolyte and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 6. Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 7. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 8. Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania. 9. Division of General Internal Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Abstract
Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce deaths from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney disease among patients with type 2 diabetes. Black individuals have a disproportionate burden of cardiovascular and chronic kidney disease (CKD). Adoption of novel therapeutics has been slower among Black and female patients and among patients with low socioeconomic status than among White or male patients or patients with higher socioeconomic status. Objective: To assess whether inequities based on race/ethnicity, gender, and socioeconomic status exist in SGLT2 inhibitor use among patients with type 2 diabetes in the US. Design, Setting, and Participants: This retrospective cohort study of commercially insured patients in the US was performed from October 1, 2015, to June 30, 2019, using the Optum Clinformatics Data Mart. Adult patients with a diagnosis of type 2 diabetes, including those with heart failure with reduced ejection fraction (HFrEF), atherosclerotic cardiovascular disease (ASCVD), or CKD, were evaluated in the analysis. Main Outcomes and Measures: Prescription of an SGLT2 inhibitor. Multivariable logistic regression models were used to assess the association of race/ethnicity, gender, and socioeconomic status with SGLT2 inhibitor use. Results: Of 934 737 patients with type 2 diabetes (mean [SD] age, 65.4 [12.9] years; 50.7% female; 57.6% White), 81 007 (8.7%) were treated with an SGLT2 inhibitor during the study period. Between 2015 and 2019, the percentage of patients with type 2 diabetes treated with an SGLT2 inhibitor increased from 3.8% to 11.9%. Among patients with type 2 diabetes and cardiovascular or kidney disease, the rate of SGLT2 inhibitor use increased but was lower than that among all patients with type 2 diabetes (HFrEF: 1.9% to 7.6%; ASCVD: 3.0% to 9.8%; CKD: 2.1% to 7.5%). In multivariable analyses, Black race (adjusted odds ratio [aOR], 0.83; 95% CI, 0.81-0.85), Asian race (aOR, 0.94; 95% CI, 0.90-0.98), and female gender (aOR, 0.84; 95% CI, 0.82-0.85) were associated with lower rates of SGLT2 inhibitor use, whereas higher median household income (≥$100 000: aOR, 1.08 [95% CI, 1.05-1.10]; $50 000-$99 999: aOR, 1.05 [95% CI, 1.03-1.07] vs <$50 000) was associated with a higher rate of SGLT2 inhibitor use. These results were similar among patients with HFrEF, ASCVD, and CKD. Conclusions and Relevance: In this cohort study, use of an SGLT2 inhibitor treatment increased among patients with type 2 diabetes from 2015 to 2019 but remained low, particularly among patients with HFrEF, CKD, and ASCVD. Black and female patients and patients with low socioeconomic status were less likely to receive an SGLT2 inhibitor, suggesting that interventions to ensure more equitable use are essential to prevent worsening of well-documented disparities in cardiovascular and kidney outcomes in the US.
Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce deaths from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney disease among patients with type 2 diabetes. Black individuals have a disproportionate burden of cardiovascular and chronic kidney disease (CKD). Adoption of novel therapeutics has been slower among Black and female patients and among patients with low socioeconomic status than among White or male patients or patients with higher socioeconomic status. Objective: To assess whether inequities based on race/ethnicity, gender, and socioeconomic status exist in SGLT2 inhibitor use among patients with type 2 diabetes in the US. Design, Setting, and Participants: This retrospective cohort study of commercially insured patients in the US was performed from October 1, 2015, to June 30, 2019, using the Optum Clinformatics Data Mart. Adult patients with a diagnosis of type 2 diabetes, including those with heart failure with reduced ejection fraction (HFrEF), atherosclerotic cardiovascular disease (ASCVD), or CKD, were evaluated in the analysis. Main Outcomes and Measures: Prescription of an SGLT2 inhibitor. Multivariable logistic regression models were used to assess the association of race/ethnicity, gender, and socioeconomic status with SGLT2 inhibitor use. Results: Of 934 737 patients with type 2 diabetes (mean [SD] age, 65.4 [12.9] years; 50.7% female; 57.6% White), 81 007 (8.7%) were treated with an SGLT2 inhibitor during the study period. Between 2015 and 2019, the percentage of patients with type 2 diabetes treated with an SGLT2 inhibitor increased from 3.8% to 11.9%. Among patients with type 2 diabetes and cardiovascular or kidney disease, the rate of SGLT2 inhibitor use increased but was lower than that among all patients with type 2 diabetes (HFrEF: 1.9% to 7.6%; ASCVD: 3.0% to 9.8%; CKD: 2.1% to 7.5%). In multivariable analyses, Black race (adjusted odds ratio [aOR], 0.83; 95% CI, 0.81-0.85), Asian race (aOR, 0.94; 95% CI, 0.90-0.98), and female gender (aOR, 0.84; 95% CI, 0.82-0.85) were associated with lower rates of SGLT2 inhibitor use, whereas higher median household income (≥$100 000: aOR, 1.08 [95% CI, 1.05-1.10]; $50 000-$99 999: aOR, 1.05 [95% CI, 1.03-1.07] vs <$50 000) was associated with a higher rate of SGLT2 inhibitor use. These results were similar among patients with HFrEF, ASCVD, and CKD. Conclusions and Relevance: In this cohort study, use of an SGLT2 inhibitor treatment increased among patients with type 2 diabetes from 2015 to 2019 but remained low, particularly among patients with HFrEF, CKD, and ASCVD. Black and female patients and patients with low socioeconomic status were less likely to receive an SGLT2 inhibitor, suggesting that interventions to ensure more equitable use are essential to prevent worsening of well-documented disparities in cardiovascular and kidney outcomes in the US.
Authors: Cynthia Delgado; Mukta Baweja; Deidra C Crews; Nwamaka D Eneanya; Crystal A Gadegbeku; Lesley A Inker; Mallika L Mendu; W Greg Miller; Marva M Moxey-Mims; Glenda V Roberts; Wendy L St Peter; Curtis Warfield; Neil R Powe Journal: J Am Soc Nephrol Date: 2021-09-23 Impact factor: 10.121
Authors: Girish N Nadkarni; Dipti Takale; Bruce Neal; Kenneth W Mahaffey; Yshai Yavin; Michael K Hansen; Fergus Fleming; Hiddo J L Heerspink; Steven G Coca Journal: Kidney360 Date: 2022-05-18
Authors: Julio A Lamprea-Montealegre; Erin Madden; Sri Lekha Tummalapalli; Carmen Peralta; Torsten B Neilands; Paola K Garcia; Anthony Muiru; Leah Karliner; Michael G Shlipak; Michelle M Estrella Journal: JAMA Date: 2022-09-06 Impact factor: 157.335
Authors: Min Zhuo; Jiahua Li; Leo F Buckley; Sri Lekha Tummalapalli; David B Mount; David J R Steele; David J Lucier; Mallika L Mendu Journal: Kidney360 Date: 2022-01-19
Authors: Chelsea E Hawley; Julie C Lauffenburger; Julie M Paik; Deborah J Wexler; Seoyoung C Kim; Elisabetta Patorno Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112